321 related articles for article (PubMed ID: 35933246)
1. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
2. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
3. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
5. CRL4
Barankiewicz J; Salomon-Perzyński A; Misiewicz-Krzemińska I; Lech-Marańda E
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139651
[TBL] [Abstract][Full Text] [Related]
6. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
[TBL] [Abstract][Full Text] [Related]
7. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
8. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
9. High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system.
Heim C; Hartmann MD
Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):290-298. PubMed ID: 35234143
[TBL] [Abstract][Full Text] [Related]
10. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
Tao J; Yang J; Xu G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
[TBL] [Abstract][Full Text] [Related]
11. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
Costacurta M; He J; Thompson PE; Shortt J
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
[TBL] [Abstract][Full Text] [Related]
13. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
[TBL] [Abstract][Full Text] [Related]
14. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
Ito T; Yamaguchi Y; Handa H
Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
[TBL] [Abstract][Full Text] [Related]
15. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
17. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.
Liu L; Sun R; Liu H; Ren C; Zhou Y; Qiu X; Kong Y; Jiang B; Yang X
Eur J Med Chem; 2023 Feb; 247():115016. PubMed ID: 36577219
[TBL] [Abstract][Full Text] [Related]
19. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
20. Ligands for cereblon: 2017-2021 patent overview.
Kazantsev A; Krasavin M
Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
